HK Stock Market Move | HBM HOLDINGS-B(02142) rose by more than 4% and deepened cooperation with AstraZeneca to jointly develop a new generation of tumor biotherapy.

HBM HOLDINGS-B (02142) rose by over 4%, reaching 4.25% by the time of publication, to HK$14.22 with a trading volume of HK$27.8477 million. On the news front, Hen Bo Medicine and AstraZeneca announced that they will update and deepen their global strategic cooperation established in March 2025. In this collaboration, both parties will jointly discover and develop a new generation of biopharmaceuticals, including antibody-drug conjugates (ADCs) and T cell engagers (TCE), based on their respective expertise. According to the agreement, AstraZeneca will nominate research and development projects annually for Hen Bo Medicine in the next four years and obtain the option to license these projects, demonstrating the continued deepening of their partnership. Hen Bo Medicine will be eligible to receive option fees, option exercise fees, development and commercial milestone payments, and tiered royalties based on future net sales of the licensed projects. The economic terms are consistent with the financial framework agreed upon by both parties in March 2025.